Table 2.
Conjoint attributes and levels.
| Attributes | Levels |
|---|---|
| Country of invention/development | Own country (ref. category) |
| United States | |
| Germany | |
| Russia | |
| China | |
| Another country | |
| Country of production | Own country (ref. category) |
| United States | |
| Germany | |
| Russia | |
| China | |
| Another country | |
| Efficacy rate | 55% (ref. category) |
| 65% | |
| 75% | |
| 85% | |
| 95% | |
| Duration of the vaccine protection | 6 months (ref. category) |
| 1 year | |
| 2 years | |
| 5 years | |
| Number of doses | 1 injection (ref. category) |
| 2 injections, at least 21 days apart | |
| 3 injections, at least 21 days apart | |
| Vaccine technology | RNA (ref. category) |
| Viral vector | |
| Whole virus | |
| Protein subunit | |
| Other vaccines using the same vaccine technology | No other licensed vaccines (ref. category) |
| Ebola | |
| Whooping cough, Rabies, Hepatitis A, etc. | |
| Hepatitis B | |
| Actors who have publicly endorsed the vaccine | Unspecified (ref. category) |
| Government official leaders | |
| Opposition party leaders | |
| Famous soccer players | |
| Famous entertainers | |
| Leading entrepreneurs | |
| Medical professionals | |
| Testing Sites | Over 20 countries, including the U.S. |
| FDA Authorization | Yes |